|Mr. Robert Farrell J.D.||CEO, Pres & Director||353k||N/A||N/A|
|Ms. Victoria Diana Rudman||Interim CFO, Treasurer & Sec.||53k||N/A||1968|
|Mr. Seth Yakatan||Co-Founder||N/A||N/A||1970|
|Dr. Stuart L. Silverman M.D., FACP, FACR||Co-Chair of Scientific Advisory Board and VP of Medical Affairs||N/A||N/A||1947|
|Dr. Sari Prutchi-Sagiv Ph.D.||Chief Scientific Officer||N/A||N/A||N/A|
Kalytera Therapeutics, Inc., a clinical-stage specialty pharmaceutical company, develops cannabinoid medicines for a range of unmet medical needs. It is developing cannabidiol formulations to prevent and treat acute graft versus host diseases. The company is also developing K-1032, a prodrug for the treatment of chronic inflammatory skin diseases, such as acne vulgaris; K-1012, a prodrug for the treatment of adult respiratory distress syndrome; K-1022, a prodrug to treat ulcerative colitis; and K-1052, a prodrug for the treatment of sepsis-induced acute renal failure and traumatic brain injury. Kalytera Therapeutics, Inc. was founded in 2014 and is headquartered in San Rafael, California.
Kalytera Therapeutics, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.